Objective: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare and potentially fatal adverse skin reactions that are most commonly triggered by certain medications. One class of medications that has been highly associated with SJS/TEN reactions is antiepileptic drugs (AEDs). We sought to quantify the risk of SJS/TEN associated with AEDs as a class, as well as individual AEDs, in the United States. 
| INTRODUCTION
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare and life-threatening, adverse skin reactions that are often triggered by particular medications. Medications that have been shown to trigger these reactions include antiepileptic drugs (AEDs), nonsteroidal antiinflammatory drugs (NSAIDs), and certain antibiotics. [1] [2] [3] Although these reactions were thought initially to be separate conditions, they are now considered part of the same continuum. SJS is defined as detachment of less than 10% of total body surface area (BSA). 4 TEN is defined as detachment of greater than 30% of total BSA. 4 Estimated incidence of these reactions is 1.5-8.3 cases per 1 000 000 person-years. [5] [6] [7] Mortality from SJS is approximately 5%, whereas mortality from TEN occurs in approximately 30% of patients. 8 Mortality risk continues after presentation of SJS/TEN, with studies showing mortality even 1 year after hospitalization. 9, 10 Severity of disease appears to be the largest risk factor for mortality in the early phase of disease, and older age and comorbidities are the largest mortality risk factors for the 3-12 month timeframe. 11 Patients who survive SJS/TEN reactions are at a high risk of developing long-term complications involving the skin, eye, or mucosa, or respiratory, renal, and/or hepatic systems. 10, 11 Epilepsy is one of the most common neurologic disorders worldwide and is classified as a chronic disorder of recurrent unprovoked seizures. 12 Approximately 3% of the population younger than the age of 75 is diagnosed with epilepsy. 13 Some AEDs have additional US Food and Drug Administration (FDA)-approved indications outside of epilepsy including the following: neuropathic pain, migraines, anxiety, insomnia, and bipolar disorder, among others. 14 Therefore, the use of these agents extends beyond patients with epilepsy, making them commonly prescribed. AEDs are associated with SJS/TEN reactions, in particular lamotrigine and carbamazepine, as they have black box warnings regarding SJS/TEN reactions. 15, 16 The black box warning for carbamazepine relates specifically to patients with the human leukocyte antigen (HLA)-B*1502 allele, as this has been found to increase the risk of developing SJS/TEN. 15 The HLA-B*1502 allele is found mostly in patients of Asian ancestry. As such, genetic screening for the HLA-B*1502 allele is recommended for patients of Asian ancestry prior to initiating carbamazepine. 15 Although not indicated with a black box warning, the package insert for oxcarbazepine also recommends genetic screening for the HLA-B*1502 allele because of the drug's chemical structure, which is similar to that of carbamazepine, along with clinical and nonclinical data suggesting an increased risk of SJS/TEN in patients taking this drug. 17 In recent years, several case-control studies and analyses of adverse-event reporting systems in Europe have explored the relationship between SJS/TEN and certain AEDs, specifically carbamazepine, lamotrigine, and phenytoin. 18, 19 However, the class effect and impact of other AEDs are not well-described. As such, we sought to quantify the risk of SJS/TEN associated with AEDs as a class, as well as individual AEDs, in the United States.
| METHODS
We reviewed adverse-event reports from the US Food and Drug Administration Adverse Event Reporting System (FAERS) for the 42-month timeframe of July 2014 through December 2017. 20 Follow-up reports were excluded, along with duplicate reports and reports missing event date, sex, and age. We conducted searches of the medical dictionary for regulatory activities (MedRA) terms "Stevens-Johnson syndrome" and "toxic epidermal necrolysis." Subsequent listings of adverse events were reviewed for inclusion. We included AEDs with an FDA indication for epilepsy or seizures (Table 1) . Reports using brand names were categorized under their generic names. Because SJS and TEN are part of the same continuum, these reactions were combined as SJS/TEN. The proportional reporting ratio (PRR), reporting odds ratio (ROR), and corresponding 95% confidence intervals (CIs) for SJS/TEN were calculated for each AED medication compared to all other non-AEDs. The ROR, PRR, and corresponding 95% CI were also calculated for the entire
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• Although several antiepileptic drugs (AEDs) have been associated with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), the class effect and impact of other AEDs are not well-described • We sought to quantify the risk of SJS/TEN with AEDs using the US Food and Drug Administration Adverse Event Reporting System (FAERS) • For AEDs as a class, the reporting odds ratio (ROR) for SJS/TEN was 8.7 (95% CI 7. Figures 1 and 2 ).
| DISCUSSION
The results of study show that SJS/TEN reporting rates were significantly higher with AEDs compared to all other medications (non-AEDs with lamotrigine compared to the other AED comparators, in our study, the ROR for lamotrigine was 53.0 (95% CI 43.2-64.9), more than twofold that of phenytoin (26.3, 95% CI 15.5-44.7) and carbamazepine (24.5, 95% CI 16.0-37.5). In our study, there were no reports of SJS/TEN reaction with phenobarbital. One possible reason for this is the declining utilization of phenobarbital, which has become a nonpreferred therapy option in treatment guidelines due to (1) its less favorable side effect profile, (2) inclusion in the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults, (3) unfavorable pharmacokinetic properties, and (4) multiple drug-drug interactions. [36] [37] [38] In 2 studies that utilized data from adverse-event reporting systems, AEDs were among the top medications associated with SJS/TEN. reactions may be associated with the starting dose and rate of titration for some AEDs. 42, 43 An approach to preventing cutaneous reactions such as SJS/TEN in AEDs, is to use a low starting dose and slow titration schedule, as has been used with lamotrigine. 44 Further research is needed to see which AEDs pose the highest risk for SJS/TEN, based on dose and titration schedule, to determine whether lower starting doses and slow titration schedules would decrease occurrences of SJS/TEN. There were several limitations to our study. Incidence and prevalence cannot be calculated, as the total number of patients using these medications is undetermined. 45 Due to the voluntary nature of reporting to FAERS, underreporting is expected. 46 A reporting bias that may have influenced the number of reactions reported is the Weber effect, 47 in which adverse-event reporting starts to decline in the 2 years after market introduction. 48 All of the AEDs included in our study with reports of SJS/TEN have been on the market for more than 2 years, with the exception of eslicarbazepine, and therefore decreases in reporting likely occurred over time. Another known limitation of the FAERS database is that causality between the adverse event and medication does not have to be established for a report to be submitted, which may be further complicated by concomitant medications and patient comorbidities. 46 In addition, drugs with frequent side effects can increase the number of overall adverse effects and therefore decrease ROR and PRR. 49 This may have occurred in our study, since the 2 medications with the most adverse reaction reports (pregabalin and gabapentin) were tied for the eighth most SJS/TEN reactions but had 2 of the 3 lowest RORs and PRRs. Whereas 2 of the 3 highest RORs and PRRs were among medications with only one SJS/TEN reaction (rufinamide and clorazepate) and they had the 2 lowest total adverse-reaction reports. Because there was only one report of SJS/TEN with clorazepate and rufinamide, the CIs of the ROR and PRR were large, and although statistically significant, the magnitude of the lower end of the CI was closer to that of the overall class. The magnitude and statistical significance of these associations may change as more adverse-event reports are submitted for clorazepate and rufinamide.
| CONCLUSION
Our study supports previous evidence that certain AEDs are associated with a higher risk of SJS/TEN, in particular, lamotrigine, phenytoin, and carbamazepine. Furthermore, we identified 8 other AEDs significantly associated with SJS/TEN: zonisamide, rufinamide, clorazepate, valproic acid, eslicarbazepine, oxcarbazepine, clonazepam, and levetiracetam. Although AEDs as a class were associated with 9 times the risk of SJS/TEN compared with non-AEDs, there were 6 AEDs with risk estimates higher than 20. Increased awareness of this risk among both prescribers and patients, particularly variations in risk among different AEDs, along with education on early recognition of SJS/ TEN signs/symptoms, may help mitigate the number and severity of these adverse events.
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